TL;DR: Aetna, a CVS Health company, modified CPB 1063 covering imetelstat (Rytelo), effective September 26, 2025. Precertification is required for all participating providers and members in applicable plan designs — and if your team isn't set up for that workflow before claims go out, you'll get denials.
This policy update to the Aetna imetelstat coverage policy governs a relatively new drug with a narrow indicated population and a high cost profile. CPB 1063 in the Aetna system sits under commercial medical plans — Medicare criteria are handled separately through Aetna's Medicare Part B step process. The policy does not list specific CPT or HCPCS codes in the current data set, which creates a billing challenge your team needs to address before submitting claims.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Imetelstat (Rytelo) — CPB 1063 |
| Policy Code | CPB 1063 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Specialty Pharmacy, Hospital Outpatient |
| Key Action | Set up precertification workflow using (866) 752-7021 before submitting any imetelstat claims under commercial Aetna plans |
Aetna Imetelstat (Rytelo) Coverage Criteria and Medical Necessity Requirements 2025
The central fact of CPB 1063 is this: precertification is mandatory. Full stop. Every Aetna participating provider and every member in an applicable commercial plan design must go through precertification before imetelstat is administered or dispensed.
This isn't a soft utilization management requirement. It's a hard prior authorization gate. Claims submitted without a valid precertification approval will face claim denial — and imetelstat is not a drug where a single denied claim is a rounding error. It's an FDA-approved telomerase inhibitor for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have relapsed or are refractory to erythropoiesis-stimulating agents. The drug carries a significant cost burden. Denials on this class of drug hurt.
The Aetna imetelstat coverage policy under CPB 1063 applies to commercial medical plan designs only. If your patient has Aetna Medicare coverage, stop here — those criteria are governed through a separate Aetna Medicare Part B step process, and you need to check that pathway independently. Mixing up the two is an easy mistake that costs you time and reimbursement.
The policy does not publish detailed medical necessity criteria in the publicly available CPB 1063 summary at this time. What it does make clear is that precertification is the entry point for establishing medical necessity documentation. You won't get a coverage determination without it. That makes the prior authorization request the most important document your clinical and billing teams will produce for these patients.
To initiate precertification, call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity forms, use Aetna's Specialty Pharmacy Precertification portal at the link in their health care professional forms section. Get familiar with that portal now, before a patient is sitting in an infusion chair waiting for authorization.
Coverage Indications at a Glance
The current CPB 1063 data does not publish a full indication-by-indication breakdown in the publicly available summary. What the policy establishes clearly is the precertification requirement and the commercial plan scope. The table below reflects what the data supports.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Imetelstat (Rytelo) under commercial Aetna medical plans | Requires Precertification | Not specified in current policy data | Call (866) 752-7021 or fax (888) 267-3277 for precertification |
| Medicare patients on Aetna plans | Governed separately | Not part of CPB 1063 | See Aetna Medicare Part B step criteria |
If the full clinical criteria — response thresholds, prior therapy requirements, diagnosis specifics — are published in Aetna's internal policy document or the member-facing plan documents, your compliance officer or specialty pharmacy team should pull those. The public-facing CPB summary establishes the administrative framework. The clinical detail lives in the full bulletin.
Aetna Imetelstat Billing Guidelines and Action Items 2025
The effective date is September 26, 2025. If you're billing imetelstat under commercial Aetna plans and you haven't already set up your precertification workflow, you're late. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Set up the precertification request process immediately. Designate who on your team initiates the precertification call to (866) 752-7021. This should be a named person with a backup — not "whoever has time." Imetelstat patients often have narrow treatment windows. |
| 2 | Pull the Statement of Medical Necessity form from Aetna's Specialty Pharmacy Precertification portal. Complete this form before the first administration. Missing or incomplete SMN forms are one of the most common precertification failure points. Check the form against your clinical documentation before you submit. |
| 3 | Confirm the applicable plan design before billing. CPB 1063 applies to commercial medical plans. It does not govern Aetna Medicare plans. Verify the patient's plan type at the time of precertification — not at the time of claim submission. |
| 4 | Identify the correct HCPCS code for imetelstat billing. The policy does not list specific codes in the current data. Contact your specialty pharmacy partner and Aetna's provider relations team to confirm the HCPCS J-code or equivalent code required for claim submission. Do not submit without confirming this — a missing or incorrect code is a straight path to claim denial. |
| 5 | Document the precertification approval number on every claim. Whatever authorization number Aetna issues through the precertification process, attach it to the claim. This is your claim-level protection if a denial comes back questioning whether precertification was obtained. |
| 6 | Audit your existing imetelstat claims under commercial Aetna plans. If you've submitted claims for imetelstat (Rytelo) on commercial Aetna members without precertification, pull those claims now. Identify any that are pending or recently denied. Retroactive authorization may be possible in limited circumstances, but you need to move fast. Talk to your compliance officer before attempting retroactive authorization requests. |
| 7 | Don't use the Medicare Part B step pathway for commercial patients. It seems obvious, but in high-volume billing environments, the wrong pathway gets used. CPB 1063 is commercial only. Flag this in your payer contract notes. |
The real issue here is that high-cost specialty drugs like imetelstat create outsized financial exposure when precertification breaks down. One missed precertification on a multi-infusion course of therapy isn't a small billing error. Build the workflow so the precertification happens before the drug is ordered, not after it's administered.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Imetelstat (Rytelo) Under CPB 1063
The current CPB 1063 policy data does not list specific CPT, HCPCS, or ICD-10 codes. This is a meaningful gap for imetelstat billing, and your team should not treat it as permission to assign codes without verification.
What to Do About Missing Codes
This is one of those situations where you need to make a direct call. Contact Aetna provider relations and ask specifically: what HCPCS code does Aetna require for imetelstat (Rytelo) claims under commercial medical plans? The drug received FDA approval in June 2024, and HCPCS J-code assignment for new specialty drugs can lag behind clinical deployment by months. Your specialty pharmacy dispenser should have the most current coding guidance — they're tracking this closely because their reimbursement depends on it.
Your billing team should also check CMS HCPCS quarterly updates. New J-codes are assigned on a quarterly cycle, and imetelstat may have received a permanent code after the most recent update cycle. Cross-reference what CMS publishes with what Aetna will accept before your charge capture is finalized.
Do not submit a "not otherwise classified" code without first confirming Aetna's preference. Some payers require the NOC code with a drug-specific description. Others have assigned a permanent code that supersedes the NOC. Filing the wrong one — even with good documentation — triggers a claim denial that takes weeks to resolve.
If you're unsure how to handle the coding gap for imetelstat billing, loop in your billing consultant or compliance officer before the September 26, 2025 effective date changes create a backlog of unanswered claims.
Why This Policy Modification Matters for Specialty Billing Teams
The modification to CPB 1063 as of September 26, 2025, is not a clinical coverage expansion or a new exclusion. It's a reaffirmation and likely a refinement of the administrative requirements around a high-cost specialty drug. That matters because payers update precertification policies on drugs like imetelstat when they're seeing utilization patterns they want to manage more tightly.
Read that signal correctly: Aetna is paying attention to imetelstat use. Your clinical documentation supporting medical necessity needs to be airtight. The SMN form isn't a formality — it's your first and best opportunity to establish that the patient meets criteria. Weak documentation at the precertification stage doesn't just risk a denial. It creates a record that follows the patient through any appeal.
If your practice is a hematology or oncology group treating MDS patients, you likely already have a specialty pharmacy relationship in place. Make sure that partner knows CPB 1063 was modified and that precertification on all commercial Aetna plans is required. The specialty pharmacy often initiates the prior authorization process, but your clinical team has to provide the documentation. Both sides of that workflow need to be current on this policy.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.